UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 26,929 Shares of The Clorox Company $CLX

Key Points

• UBS Asset Management reduced its Clorox stake by 2.2% in the second quarter, selling 26,929 shares and retaining 1.21 million shares valued at approximately $115.5 million. Institutional investors collectively own 78.53% of CLX.
• Analyst sentiment remains cautious: Clorox has a consensus “Reduce” rating, with 12 Holds and five Sells and an average price target of $102.40.
• Clorox exceeded quarterly earnings and revenue estimates, reporting $1.66 in EPS and $1.95 billion in revenue, but sales fell 2% year over year. The company increased its quarterly dividend to $1.25 per share, representing a 5.3% annualized yield.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in The Clorox Company (NYSE:CLX - Free Report) by 2.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,210,527 shares of the company's stock after selling 26,929 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.00% of Clorox worth $115,533,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. Caitlin John LLC boosted its holdings in Clorox by 1,807.1% in the 4th quarter. Caitlin John LLC now owns 267 shares of the company's stock worth $27,000 after buying an additional 253 shares during the period. Ancora Advisors LLC bought a new stake in Clorox during the 2nd quarter valued at $28,000. Avalon Trust Co bought a new stake in Clorox during the 2nd quarter valued at $29,000. Darwin Wealth Management LLC purchased a new stake in shares of Clorox during the second quarter worth $29,000. Finally, Root Financial Partners LLC lifted its position in shares of Clorox by 83.8% during the first quarter. Root Financial Partners LLC now owns 318 shares of the company's stock worth $33,000 after acquiring an additional 145 shares in the last quarter. 78.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CLX. Zacks Research cut Clorox from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 12th. Wells Fargo & Company increased their price objective on Clorox from $95.00 to $102.00 and gave the stock an "equal weight" rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. raised their target price on Clorox from $92.00 to $95.00 and gave the stock an "underweight" rating in a research note on Tuesday, August 4th. Wall Street Zen lowered Clorox from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Finally, BNP Paribas Exane decreased their price target on Clorox from $97.00 to $95.00 and set a "neutral" rating on the stock in a research report on Monday, July 20th. Twelve analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Reduce" and a consensus target price of $102.40.

Clorox Stock Down 2.8%

CLX stock opened at $94.99 on Wednesday. The company's 50 day moving average is $100.03 and its 200 day moving average is $102.22. The stock has a market cap of $11.49 billion, a price-to-earnings ratio of 19.71, a price-to-earnings-growth ratio of 3.06 and a beta of 0.56. The company has a current ratio of 0.66, a quick ratio of 0.38 and a debt-to-equity ratio of 15.80. The Clorox Company has a 1-year low of $84.70 and a 1-year high of $128.90.

Clorox (NYSE:CLX - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.02. The company had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.91 billion. Clorox had a net margin of 8.74% and a return on equity of 522.23%. The firm's quarterly revenue was down 2.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.87 earnings per share. Clorox has set its FY 2027 guidance at 5.700-6.000 EPS. Sell-side analysts predict that The Clorox Company will post 5.8 EPS for the current fiscal year.

Clorox Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, August 28th. Investors of record on Wednesday, August 12th were issued a dividend of $1.25 per share. The ex-dividend date was Wednesday, August 12th. This represents a $5.00 annualized dividend and a yield of 5.3%. This is a boost from Clorox's previous quarterly dividend of $1.24. Clorox's dividend payout ratio (DPR) is currently 103.73%.

Clorox Profile

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company's flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox's diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source